Tarceva Added To Gemcitabine Improves Pancreatic Cancer Survival, Study Finds
Finasteride Could Save Many Years Of Life If Widely Used For Prostate Cancer Prevention
Center Studies Prevention For Endometrial Cancer
Fruit, Vegetables Don’t Prevent Protect Against Breast Cancer
Men With PSA Of 7 Or Higher More Likely To Have Biopsy
Northwestern To Test Method To Detect Colon Cancer
Treatment Doesn’t Always Follow Recommendations
Transplant Is Viable Option For HIV+ Patients, Study Finds
QOL Of Young Survivors Equal To Other Children
High-Dose Chemo Can Cure Rare Pediatric Brain Tumor
MRI Predicts If Chemo Working In Preoperative Therapy
Clinical Trials Approved By NCI’s CTEP Listed
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
